Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026595 | 0.84 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL128122 | 0.80 | RAB9A (0.34) | MEN1KMT2A | |
| SCHEMBL1303572 | 0.79 | ATM (0.41) | MEN1KMT2A | |
| SCHEMBL8695815 | 0.79 | — | — | |
| SCHEMBL19517200 | 0.79 | ATM (0.41) | MEN1KMT2A | |
| SCHEMBL1613168 | 0.79 | ATM (0.41) | MEN1KMT2A | |
| SCHEMBL1489692 | 0.79 | RAB9A (0.39) | — | |
| SCHEMBL23278004 | 0.77 | HRH3 (0.39) | MEN1KMT2A | |
| SCHEMBL15955855 | 0.77 | MAOB (0.43) | MEN1KMT2A | |
| SCHEMBL1303845 | 0.77 | MAOB (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | disclosed |
| EP-2499129-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011058108-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| EP-1737815-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100308-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, MAP2K2, PDPK1 | MEN1 2524/4885KMT2A 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.